Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Sword Health nabs $40M at $4B valuation, pushes IPO plans to at least 2028

From TechCrunch

By Marina Temkin

June 17, 2025

Sword Health nabs $40M at $4B valuation, pushes IPO plans to at least 2028

Sword Health nabs $40M at $4B valuation, pushes IPO plans to at least 2028

Sword Health, an AI-powered digital health startup, has raised $40 million at a $4 billion valuation, a 33% jump from the $3 billion price tag it earned just a year ago. The funding was led by returning investor General Catalyst.

Even though 10-year-old Sword Health is cash-flow positive, its CEO and founder, Virgílio Bento, told TechCrunch that he opted to raise additional capital for two key reasons: to update the company’s valuation, and have funds readily available for strategic acquisitions.

Sword Health, which began as a virtual physical therapist and has since expanded into offering pelvic health and mental health services, had previously considered a near-term IPO. Bento told TechCrunch last year that a 2025 listing was a possibility.

Despite the recent successful IPOs of counterparts Hinge Health and Omada, and Sword’s healthy $240 million annual revenue run rate, Bento is reconsidering his IPO plans.

“It’s going to be much later than everyone expects,” he said.

Bento’s goal is for Phoenix, Sword’s AI care specialist, to extend remote healthcare beyond musculoskeletal pain and pelvic floor care to numerous conditions, such as cardiovascular care, gastroenterological health, and speech therapy.

“I want to IPO when I have lots of different proof points at scale in many different care verticals — so maybe 2028,” he said.

In recent months, Bento has embarked on what he calls an “educational journey” to learn about managing a public company, speaking with CEOs of various public companies and bankers.

“At the end of that education period, I realized that if you ask me why we shouldn’t IPO, I can give you 10 reasons. If you ask me why we should IPO, I cannot find one reason,” he said.

Bento isn’t convinced by the typical reasons for an IPO, such as brand building or capital access. Pointing to Ikea and Lego as examples of successful private companies, he said strong startups can still secure ample private capital, citing Databricks’ massive $10 billion raise.

Liquidity for employees and early shareholders is also easily attainable for private companies thanks to secondary markets, Bento said, adding that Sword will likely launch a tender offer next month.

Sword expects to raise more capital next year, Bento said. He’s even predicting the size and valuation of the company’s next funding round.

“Last year, we raised $30 million at a $3 billion valuation. This year, we did $40 million at $4 billion. I think you can imagine the type of raise we’re going to do next year, which is probably going to be $50 million at $5 billion,” he said. “I like the numerical symmetry. I think it’s fun.”

The latest round brings Sword’s total funding to $380 million. Other participants in the new round include Khosla Ventures, Comcast Ventures, Lince Capital, Oxy Capital, Armilar, Indico Capital, and Shilling.

View original article on techcrunch.com

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

From Skims to Stripe, here are the startups that are likely — or definitely — not having IPOs this year

From Skims to Stripe, here are the startups that are likely — or definitely — not having IPOs this year

Last year’s investor dreams of a strong 2024 IPO pipeline have faded, if not fully disappeared, as we settle in to the second half of the year. This year delivered four venture-backed tech IPOs — Reddit, Astera Labs, Ibotta and Rubrik — in March and April, which made it seem like this year could spur the momentum investors had hoped for in 2023. But secondary investors and IPO lawyers recently told TechCrunch that despite these four successes, macro conditions like the upcoming presidential ele

Aug 7, 2024

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI, a startup building AI solutions that can handle non-diagnostic patient-facing tasks, secured a massive $141 million Series B at a valuation of $1.64 billion led by Kleiner Perkins, the company announced Thursday. The funding comes nine months after Hippocratic AI raised a $53 million round from General Catalyst and Andreessen Horowitz and five months after raising $17 million from Nvidia. The startup is less than two years old. While most healthcare-generative AI companies focus

Jan 9, 2025

Heidi Health raises $65M Series B led by Steve Cohen’s Point72 Private Investments

Heidi Health raises $65M Series B led by Steve Cohen’s Point72 Private Investments

Heidi Health raised a $65 million Series B led by Steven Cohen’s Point72 Private Investments.

Oct 5, 2025

Whoop’s valuation just tripled to $10 billion

Whoop’s valuation just tripled to $10 billion

The fitness tracking startup just closed a $575 million Series G with Cristiano Ronaldo and LeBron James among its investors. The obvious question looming over a round of this size at this valuation: Is an IPO coming?

Mar 31, 2026

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

From Skims to Stripe, here are the startups that are likely — or definitely — not having IPOs this year

From Skims to Stripe, here are the startups that are likely — or definitely — not having IPOs this year

Last year’s investor dreams of a strong 2024 IPO pipeline have faded, if not fully disappeared, as we settle in to the second half of the year. This year delivered four venture-backed tech IPOs — Reddit, Astera Labs, Ibotta and Rubrik — in March and April, which made it seem like this year could spur the momentum investors had hoped for in 2023. But secondary investors and IPO lawyers recently told TechCrunch that despite these four successes, macro conditions like the upcoming presidential ele

Aug 7, 2024

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI raises $141M for creating patient-facing AI agents

Hippocratic AI, a startup building AI solutions that can handle non-diagnostic patient-facing tasks, secured a massive $141 million Series B at a valuation of $1.64 billion led by Kleiner Perkins, the company announced Thursday. The funding comes nine months after Hippocratic AI raised a $53 million round from General Catalyst and Andreessen Horowitz and five months after raising $17 million from Nvidia. The startup is less than two years old. While most healthcare-generative AI companies focus

Jan 9, 2025

Heidi Health raises $65M Series B led by Steve Cohen’s Point72 Private Investments

Heidi Health raises $65M Series B led by Steve Cohen’s Point72 Private Investments

Heidi Health raised a $65 million Series B led by Steven Cohen’s Point72 Private Investments.

Oct 5, 2025

Whoop’s valuation just tripled to $10 billion

Whoop’s valuation just tripled to $10 billion

The fitness tracking startup just closed a $575 million Series G with Cristiano Ronaldo and LeBron James among its investors. The obvious question looming over a round of this size at this valuation: Is an IPO coming?

Mar 31, 2026